Amgen has reached a settlement with Alexion Pharmaceuticals in patent-litigation proceedings over Soliris (eculizumab), picking up the rights to launch Amgen’s ABP 959 eculizumab biosimilar in the US from 1 March 2025, around two years ahead of various Soliris patents expiring.
A filing with the US Securities and Exchange Commission reveals the firms have entered into a confidential settlement and license agreement that dissolves three inter partes review proceedings instituted in August last year at